Home › Alzheimer's Disease › NCT07012993
Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol
Evaluation of Ultralow Dose PET Imaging for Detecting Amyloid Tracer Uptake
Who can join
Ages 18 to 120 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: Age ≥18 years; Ability to provide informed consent and comply with study procedures; For female participants: Must not be pregnant or breastfeeding; Negative pregnancy test required for women of childbearing potential. Exclusion Criteria: Participants who have exceeded NRC regulation for annual radiation exposure from prior research-related scans, including this study (50 millisievert \[mSv\] total); More than four prior enrollments in this study; Participants with severe claustrophobia, chronic pain, or musculoskeletal conditions that prevent completion of the PET scan; Pregnant or breastfeeding individuals (negative pregnancy test required); Inability to provide informed consent; Any condition that, in the investigator's judgment, may compromise participant safety or study integrity.
About the study
The goal of this clinical trial is to evaluate an investigational ultralow dose Positron Emission Tomography (PET) imaging technique for Alzheimer's disease, mild cognitive impairment, other forms of dementia detection and monitoring. The main question it aims to answer is:
Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called Fluorine-18 (18F)-Florbetapir or 18F-Flutemetamol and be imaged on a new type of high-sensitivity PET scanner for up to 3 hours
What is being tested
- 18F-Florbetapir or 18F-Flutemetamol (drug)
Sponsor: Akiva Mintz · Participants: 200 · Started: May 20, 2025
Contact the study team
- Barbara Blanchfield · Phone: 973-255-4955
Official record on ClinicalTrials.gov — NCT07012993
Locations in the U.S.
| New Jersey | Nuclear Imaging Institute, Englewood |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.